Abbott Pushes Deeper Into Cancer Testing With Exact Sciences

Abbott opened the week by making cancer diagnostics a much bigger part of its future. The company completed its acquisition of Exact Sciences, making Exact a wholly owned subsidiary of Abbott, in a deal valued at about $21 billion in equity value, or roughly $23 billion including debt. Under the original deal terms, Exact shareholders received $105 per share in cash, and March 20 was the last day of trading for Exact shares on Nasdaq. The deal gives Abbott a larger foothold in a faster-growing part of diagnostics and points directly to where the company wants more scale.

Exact brings Abbott a lineup that includes Cologuard in colorectal cancer screening, Oncotype DX in treatment guidance for early-stage breast cancer, Oncodetect in molecular residual disease testing, and Cancerguard in multi-cancer early detection. Abbott said the deal establishes leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments, which is a fairly ambitious way to spend the start of the week. The strategic attraction is that Abbott is expanding deeper into diagnostics tied to earlier detection, personalized treatment decisions, and regular monitoring.

Beneath the strategic pitch, there is also a straightforward financial case for why Abbott was willing to do this deal. The company previously said the transaction is expected to add about $3 billion of incremental sales in 2026, accelerate its 2026 sales growth by roughly 0.5%, and dilute 2026 adjusted EPS by about $0.20. Exact was expected to generate more than $3 billion in revenue this year, and Abbott said the addition would lift its total diagnostics sales above $12 billion annually. Abbott is taking a modest near-term earnings bruise in exchange for a much larger diagnostics platform, giving investors a good look at how the company is weighing short-term dilution against longer-term growth.

What gives the deal even more credibility is that Abbott is not entering this market from scratch. It is plugging Exact’s cancer franchise into a company that already knows how to scale diagnostics globally, and Abbott said Exact will keep its presence in Madison while Kevin Conroy remains in an advisory role during the transition. No acquisition this size comes without execution risk, but Abbott has at least made the objective behind the deal unusually clear. Abbott made cancer diagnostics a bigger priority with one very large transaction, and now it gets to prove the ambition was worth the price.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726